AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A process for the production of an immunogenic compound comprising the steps of

(a) inducing necrosis of tumor cells by subjecting the cells to a temperature of more than 41.2°C for at least 15 minutes ~~in tumor cells~~; and

(b) lysing said necrotic tumor cells so as to obtain a lysate.

2. (Original) The process of claim 1, wherein necrosis is induced in tumor cells selected from the group consisting of tumor cell lines, cells derived from primary tumor material, cells derived from cell populations of primary tumor material and/or metastases including micrometatases.

3. (Currently amended) The process of claim 1 [[or 2]], wherein said induction of necrosis is achieved by incubating said tumor cells at a temperature of more than 42°C.

4. (Currently amended) The process of claim 1 ~~any one of claims 1 to 3~~, wherein said induction of necrosis is achieved by incubating said tumor cells at a temperature in the range of 45°C to 55°C.

5. (Currently amended) The process of claim 1 ~~any one of claims 1 to 4~~, wherein said induction of necrosis is achieved by incubating said tumor cells at a temperature in the range of 45.5°C to 47°C.

6. (Currently amended) The process of claim 1 ~~any one of claims 1 to 5~~, wherein said induction of necrosis is performed in the range of 2 to 3 hours.

7. (Currently amended) The process of claim 1 ~~any one of claims 1 to 6~~, wherein more than 40% of said tumor cells are necrotic after induction of necrosis.

8. (Currently amended) The process of claim 1 ~~any one of claims 1 to 7~~, wherein more than 70% of said tumor cells are necrotic after induction of necrosis.

9. (Currently amended) The process of claim 1 ~~any one of claims 1 to 6~~, wherein said tumor cells are genetically engineered, mutated or infected by oncogenic viruses.

10. (Currently amended) The process of claim 1 ~~any one of claims 1 to 9~~, wherein said tumor cells are autologous and from the same or from different tissues, organs or cell origin in a species.

11. (Currently amended) The process of claim 1 ~~any one of claims 1 to 9~~, wherein said tumor cells are allogeneic.

12. (Currently amended) The process of claim 1 ~~any one of claims 1 to 9~~, wherein said tumor cells are syngenic.

13. (Currently amended) The process of claim 1 ~~any one of claims 1 to 9~~, wherein said tumor cells are xenogenic.

14. (Currently amended) The process of claim 1 ~~any one of claims 1 to 13~~, wherein more than one type of tumor cell is used and wherein the tumor cells are from the same or different individuals, tissues, cell types or tumors.

15. (Currently amended) The process of claim 1 ~~any one of claims 1 to 14~~, wherein said tumor cells are NM-F9 cells (DSMZ deposit No DSM ACCC2606) or NM-D4 cells (DSMZ deposit No. DSM ACC2605).

16. (Currently amended) A lysate obtainable by the process of claim 1 ~~any one of claims 1 to 15~~.

17. (Original) Dendritic cells loaded with the lysate of claim 16.

18. (Original) A composition comprising a lysate of claim 16 or dendritic cells of claim 17.

19. (Original) The composition of claim 18, which is a pharmaceutical composition.

20. (Original) The composition of claim 18, which is a vaccine composition.

21. (Currently amended) The pharmaceutical composition of claim 19 ~~20 or the vaccine composition of claim 20~~, which is optionally combined with an adjuvant.

22. (Currently amended) The dendritic cells of claim 17 ~~or the composition of claim 18~~, wherein said dendritic cells are immature.

23. (Currently amended) The dendritic cells of claim 17 ~~or the composition of claim 18~~, wherein said dendritic cells are mature.

24. (Original) A method for the production of a vaccine composition comprising the step of combining a cell lysate of claim 16 or the dendritic cells of claim 17 with an adjuvant.

25. (Original) A method for the production of a pharmaceutical composition comprising the step of combining a cell lysate of claim 16 with a pharmaceutically acceptable carrier.

26. (Currently amended) A method for the treatment or prevention of cancer, tumorous diseases, infections and/or autoimmune diseases in a patient in need thereof comprising administering a therapeutically or prophylactically effective amount of the

lysate of claim 16 ~~to an individual, or the pharmaceutical composition of claim 19, 21 or 22 or of the vaccine composition of any one of claims 20 to 22,~~ or the dendritic cells of claim [[~~16~~]] 17 to the patient.

27. (Canceled)

28. (Currently amended) The method of claim 26 ~~or the use of claim 27~~, wherein said cancer or tumorous disease is a cancer of the head and neck, lung, mediastinum, gastrointestinal tract, genitourinary system, gynaecological system, breast, endocrine system, skin, childhood, unknown primary site or metastatic cancer, a sarcoma of the soft tissue and bone, a mesothelioma, a melanoma, a neoplasm of the central nervous system, a lymphoma, a leukaemia, a paraneoplastic syndrome, a peritoneal carcinomastosis, a immunosuppression-related malignancy and/or metastatic cancer.

29. (Currently amended) The method of claim 26 ~~or the use of claim 27~~, wherein said infection is bacterial infection, viral infection, fungal infection, protozoal infection and/or helminthic infection.

30. (Currently amended) The method of claim 26 ~~or the use of claim 27~~, wherein said autoimmune disease is allergic encephalomyelitis, autoimmune haemolytic anemia, autoimmune thyroiditis, Hashimoto's disease, autoimmune mail infertility, bullous pemphigoid, Celiac disease, Grave's disease, Goodpasture's syndrome, idiopathic thrombocytopenic purpura, insulin-resistant diabetis mellitus, myasthenia gravis, pernicious anemia, pemphigus vulgaris, polyarteritis nodosa, primary biliary cirrhosis, Reiter's disease, rheumatic fever, sarcoidosis, Sjogren's disease, systemic

lupus erythematosus, sympathetic ophthalmia, multiple sclerosis and/or viral myocarditis by Cocksakie B virus response.

31. (New) The vaccine composition of claim 20, which is optionally combined with an adjuvant.

32. (New) The composition of claim 18, wherein the dendritic cells are immature.

33. (New) The composition of claim 20, wherein the dendritic cells are mature.

34. (New) A method for the treatment or prevention of cancer, tumorous diseases, infections and/or autoimmune diseases in a patient in need thereof comprising administering a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim 19 to the patient.

35. (New) A method for the treatment or prevention of cancer, tumorous diseases, infections and/or autoimmune diseases in a patient in need thereof comprising administering a therapeutically or prophylactically effective amount of the vaccine composition of claim 20 to the patient.